ABBVIE INC.
ABBV Real Time Price USD$ABBV stock is featured in our Dan Meuser, Rob Bresnahan, and Tom Carper strategies.
All StrategiesRecent trades of ABBV by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ABBV holdings by institutional investors
Quarterly net insider trading by ABBV's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,050,000 Oct 20, 2026 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
-
$1,160,000 Jul 20, 2026 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
-
$2,080,000 Apr 20, 2026 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
-
$1,330,000 Jan 20, 2026 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
-
$980,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
-
$1,160,000 Jul 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
-
$2,110,000 Apr 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
-
$1,080,000 Jan 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
-
$1,280,000 Oct 21, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$580,000 Jul 22, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$830,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$750,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$600,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$970,000 Jan 20, 2023 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$2,370,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$880,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$3,980,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$1,290,000 Jan 20, 2022 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$1,940,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$680,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$3,090,000 Apr 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid Trade (domestic/foreign)
-
$650,000 Jan 20, 2021 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$1,430,000 Oct 20, 2020 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$670,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$2,980,000 Apr 20, 2020 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$970,000 Jan 21, 2020 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Budget/Appropriations
-
$1,790,000 Oct 21, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$900,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$2,680,000 Apr 22, 2019 Issue: Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues
-
$1,820,000 Jan 22, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$600,000 Oct 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$790,000 Jul 20, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$2,890,000 Apr 20, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$1,280,000 Jan 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Disaster Planning/Emergencies
-
$1,200,000 Oct 20, 2017 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$720,000 Jul 20, 2017 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Budget/Appropriations
-
$2,460,000 Apr 20, 2017 Issue: Medicare/Medicaid Health Issues Trade (domestic/foreign) Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark
-
$1,040,000 Jan 20, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$2,610,000 Oct 28, 2016 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Budget/Appropriations
-
$1,920,000 Oct 20, 2016 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
-
$1,700,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Budget/Appropriations
-
$1,180,000 Jan 20, 2016 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$1,240,000 Oct 19, 2015 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
-
$930,000 Oct 19, 2015 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Trade (domestic/foreign)
-
$1,870,000 Oct 19, 2015 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign)
-
$1,010,000 Jan 20, 2015 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
-
$1,600,000 Oct 17, 2014 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Budget/Appropriations Trade (domestic/foreign)
-
$880,000 Jul 21, 2014 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Copyright/Patent/Trademark
-
$1,450,000 Apr 21, 2014 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$600,000 Jan 21, 2014 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$630,000 Oct 21, 2013 Issue: Science/Technology Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,180,000 Oct 21, 2013 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Budget/Appropriations Medicare/Medicaid
-
$770,000 Apr 22, 2013 Issue: Health Issues Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
Former government officials who have lobbied for ABBV
86 former government officials from 46 congressional offices at 16 lobbying firms have lobbied for ABBV, most recently Oct 21, 2026.
-
Paul Brathwaite Congress Executive Director, Congressional Black Caucus; Deputy Assistant Secretary, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S. Department of Labor.
-
Ven Neralla House New Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff, U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep. Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio; Senior Advisor, USDA; OPP; and MCC. -
Stacey Leavandosky House New Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation -
Kaade Wallace Senate New Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum -
Hazen Marshall Senate Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles -
Monica Popp Senate Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint -
Daniel Ziegler House Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson -
Robert Butora Senate Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
ABBV Estimated quarterly lobbying spending
ABBV Revenue by Segment or Geography
New ABBV patent grants
-
Patent Title: Bromodomain inhibitors Mar. 29, 2016
-
Patent Title: Nampt inhibitors Mar. 29, 2016
-
Patent Title: Methods to control protein heterogeneity Mar. 22, 2016
-
Patent Title: Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme Mar. 22, 2016
-
Patent Title: Methods of producing adalimumab Mar. 15, 2016
-
Patent Title: Inhibitors of histone methyltransferase g9a Mar. 15, 2016
-
Patent Title: Inhibitors of poly(adp-ribose)polymerase Mar. 15, 2016
-
Patent Title: Anti-viral compounds Mar. 08, 2016
-
Patent Title: Method for producing monolithic tablets Mar. 08, 2016
-
Patent Title: Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography Feb. 23, 2016
-
Patent Title: Low acidic species compositions and methods for producing and using the same Feb. 23, 2016
-
Patent Title: Phosphine ligands for catalytic reactions Feb. 23, 2016
-
Patent Title: Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Feb. 23, 2016
-
Patent Title: Synthesis of (2s,5r)-5-ethynyl-1-{n-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile Feb. 16, 2016
-
Patent Title: Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof Feb. 09, 2016
-
Patent Title: Methods for controlling the galactosylation profile of recombinantly-expressed proteins Feb. 09, 2016
-
Patent Title: Polymorph of a pharmaceutical Feb. 09, 2016
-
Patent Title: Process for preparing antiviral compounds Feb. 09, 2016
-
Patent Title: Purification of antibodies using hydrophobic interaction chromatography Feb. 02, 2016
-
Patent Title: Anti-viral compounds Feb. 02, 2016
-
Patent Title: Formulations of phenyl uracil compounds Feb. 02, 2016
-
Patent Title: Medicine container, method of assembling the container, and method of dispensing the medicine from the container Jan. 26, 2016
-
Patent Title: Processes for the preparation of an apoptosis-inducing agent Jan. 19, 2016
-
Patent Title: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Jan. 19, 2016
-
Patent Title: Methods to control protein heterogeneity Jan. 12, 2016
-
Patent Title: Fed-batch methods for producing adalimumab Jan. 12, 2016
-
Patent Title: Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Jan. 05, 2016
-
Patent Title: Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy Jan. 05, 2016
-
Patent Title: Process for preparing bicyclic amine derivatives Jan. 05, 2016
-
Patent Title: Tnf-α binding proteins Jan. 05, 2016
-
Patent Title: Extended release hydrocodone acetaminophen and related methods and uses thereof Jan. 05, 2016
-
Patent Title: Process for preparing antiviral compound Dec. 22, 2015
-
Patent Title: Bicyclic carboxamide inhibitors of kinases Dec. 15, 2015
-
Patent Title: Methods to control protein heterogeneity Dec. 08, 2015
-
Patent Title: Methods for transforming yeast Dec. 01, 2015
-
Patent Title: Low acidic species compositions and methods for producing and using the same Dec. 01, 2015
-
Patent Title: Low acidic species compositions and methods for producing and using the same Dec. 01, 2015
-
Patent Title: Phosphine ligands for catalytic reactions Dec. 01, 2015
-
Patent Title: Processes for the preparation of an apoptosis-inducing agent Dec. 01, 2015
-
Patent Title: Human antibodies that bind human tnf-alpha and methods of preparing the same Nov. 24, 2015
-
Patent Title: Heterocyclic nuclear hormone receptor modulators Nov. 24, 2015
-
Patent Title: Nampt inhibitors Nov. 24, 2015
-
Patent Title: Compounds as cannabinoid receptor ligands Nov. 24, 2015
-
Patent Title: Modulators of 5-ht receptors and methods of use thereof Nov. 17, 2015
-
Patent Title: Nampt inhibitors Nov. 17, 2015
-
Patent Title: Pharmaceutical compositions and their methods of use Nov. 17, 2015
-
Patent Title: Treatment of osteoarthritis pain Nov. 17, 2015
-
Patent Title: Methods to modulate lysine variant distribution Nov. 10, 2015
-
Patent Title: Modulated lysine variant species compositions and methods for producing and using the same Nov. 10, 2015
-
Patent Title: Mercaptoamidine derivatives and methods of use Nov. 10, 2015
Federal grants, loans, and purchases
- $22,915 2026-01-07 00:00:00 Agency: Department of Veterans Affairs
- $20,050 2025-12-29 00:00:00 Agency: Department of Veterans Affairs
- $21,573 2025-11-21 00:00:00 Agency: Department of Veterans Affairs
- $51,844 2025-11-14 00:00:00 Agency: Department of Health and Human Services
- $113,265 2025-10-01 00:00:00 Agency: Department of Veterans Affairs
- $164,749 2025-10-01 00:00:00 Agency: Department of Veterans Affairs
- $0 2025-07-28 00:00:00 Agency: Department of Veterans Affairs
- $0 2025-06-24 00:00:00 Agency: Department of Veterans Affairs
- $21,839 2025-05-12 00:00:00 Agency: Department of Veterans Affairs
- $6,865 2025-05-07 00:00:00 Agency: Department of Veterans Affairs
- $61,781 2025-04-16 00:00:00 Agency: Department of Veterans Affairs
- $21,869 2025-04-15 00:00:00 Agency: Department of Veterans Affairs
- $42,028 2025-02-06 00:00:00 Agency: Department of Veterans Affairs
- $47,085 2025-01-22 00:00:00 Agency: Department of Veterans Affairs
- $49,850 2024-11-21 00:00:00 Agency: Department of Health and Human Services
- $0 2024-11-12 00:00:00 Agency: Department of Veterans Affairs
- $14,355 2024-08-19 00:00:00 Agency: Department of Veterans Affairs
- $47,933 2023-12-20 00:00:00 Agency: Department of Health and Human Services
- $0 2023-12-13 00:00:00 Agency: Department of Health and Human Services
- $14,913 2023-10-10 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-09-28 00:00:00 Agency: Department of Veterans Affairs
- $14,913 2023-09-22 00:00:00 Agency: Department of Veterans Affairs
- $25,528 2023-08-12 00:00:00 Agency: Department of Veterans Affairs
- $16,200 2023-08-01 00:00:00 Agency: Department of Veterans Affairs
- $21,600 2023-04-03 00:00:00 Agency: Department of Veterans Affairs
Estimated quarterly amount awarded to ABBV from public contracts
Recent insights relating to ABBV
Pending bills that may affect ABBV
|
Bill
|
Impact
|
Confidence
|
Date
|
|---|
Recent picks made for ABBV stock on CNBC
ETFs with the largest estimated holdings in ABBV
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ABBV stock a Buy, Sell, or Hold?
- What is the price target for $ABBV stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ABBV stock?
- Who owns the most shares of $ABBV stock?
- What funds own $ABBV stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ABBV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
- Address North Chicago, IL
- Market Cap 520.7 billion
- Employees 57,000
- Industrial Classification Pharmaceutical Preparations
ABBVIE INC. (ABBV) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for ABBVIE INC. (ABBV).
Quiver Premium charts ABBV's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at ABBV, per a recent SEC DEF 14A filing. We estimate that the median employee at AbbVie Inc. is paid $134,351.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|